Keyphrases
Adjuvant Chemotherapy
13%
Adult Cancer
25%
Adverse Events
23%
Anthracycline-based Chemotherapy
9%
Anthracyclines
12%
Black Women
9%
Body Composition
36%
Body Mass Index
16%
Breast Cancer
45%
Breast Cancer Patients
17%
Breast Cancer Recurrence
9%
Cancer Patients
11%
Chemotherapy
42%
Chemotherapy Regimen
10%
Clinical Trials
8%
Comorbidity
15%
Confidence Interval
21%
Dose Reduction
11%
Early Breast Cancer
60%
Endocrine Treatment
16%
Frailty
11%
Geriatric Assessment
16%
Hazard Ratio
13%
HER2-positive
9%
Hormone Receptor
10%
Hormone Receptor-positive
13%
Hospitalization
10%
Human Epidermal Growth Factor Receptor 2 (HER2)
20%
In Cancer
14%
Meta-analysis
38%
Metastatic Breast Cancer
31%
Myosteatosis
11%
Older Adults
11%
Older Patients
12%
Older Women
12%
Overall Survival
17%
Physical Function
8%
Quality of Life
12%
Relative Risk
13%
Sarcopenia
38%
Skeletal muscle
15%
Skeletal muscle Density
17%
Skeletal muscle Gauge
11%
Skeletal muscle Index
22%
Systematic Meta-analysis
22%
Taxane-based Chemotherapy
12%
Treatment Toxicity
16%
Tumor
10%
Very Severe
9%
Weight Gain
15%
Medicine and Dentistry
Adipose Tissue
13%
Adjuvant Chemotherapy
6%
Adjuvant Therapy
5%
Advanced Cancer
8%
Adverse Event
13%
Alpelisib
8%
Anthracycline
6%
Body Mass Index
10%
Breast Cancer
100%
Breast Carcinoma
5%
Cancer Diagnosis
11%
Clinical Trial
7%
Clinician
5%
Comorbidity
14%
Computer Assisted Tomography
8%
Diseases
5%
Epidermal Growth Factor Receptor 2
6%
Frailty
11%
Gamma Urogastrone
6%
Geriatric Assessment
10%
Hazard Ratio
11%
Hormone Receptor
21%
Hormone Therapy
19%
Intraductal Carcinoma
5%
Malignant Neoplasm
39%
Meta-Analysis
34%
Metastatic Breast Cancer
21%
Metastatic Carcinoma
12%
Neoplasm
12%
Odds Ratio
6%
Oncology
11%
Overall Survival
17%
Patient Characteristics
6%
Patient-Reported Outcome
7%
Prospective Study
5%
Quality of Life
14%
Randomized Controlled Trial
5%
Recurrent Disease
8%
Sarcopenia
37%
Skeletal Muscle
40%
Solid Malignant Neoplasm
9%
Systematic Review
34%
Tumor Progression
5%